AML, acute myeloid leukaemia; Ang2, angiopoietin-2; BC, breast cancer; CLL, chronic lymphocytic leukaemia; CRPC, castration-resistant prostate cancer; DLBCL, diffuse large B-cell lymphoma; EGFR, epidermal growth factor receptor; EGFR M+, epidermal growth factor receptor mutation-positive; ErbB, epidermal growth factor receptor tyrosine kinase family receptor; FGFR, fibroblast growth factor receptor; HER2, human epidermal growth factor receptor 2; HNSCC, head and neck squamous cell carcinoma; IGF, insulin-like growth factor; iv, intravenous; LAG3, lymphocyte-activation gene-3; mCRC, metastatic colorectal cancer; MDS, myelodysplastic syndrome; mRNA-based ICV, messenger ribonucleic acid-based immunotherapeutic cancer vaccine; NBE, new biological entity; NCE, new chemical entity; NHL, non-Hodgkin lymphoma; NSCLC, non-small cell lung cancer; nsNSCLC, non-squamous non-small cell lung cancer; po, orally; PDGFR, platelet-derived growth factor receptor; PD-1, programmed cell death 1; SMAC, second mitochondria-derived activator of caspase; SqNSCLC, squamous histology non-small cell lung cancer; TKI, tyrosine kinase inhibitor; UC, urothelial carcinoma; VEGF, vascular endothelial growth factor; VEGFR, vascular endothelial growth factor receptor.